Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 12/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863998 | 1.00 | KCNN3 (0.40) | KCNN3PIK3CDPIK3R1IDH1PDE2A | |
| SCHEMBL864168 | 0.88 | PIK3CD (0.36) | KCNN3PIK3CDPIK3R1IDH1PDE2A | |
| SCHEMBL2115344 | 0.84 | OPRK1 (0.38) | KCNN3PIK3CDPIK3R1CCNT1CDK9 | |
| SCHEMBL2115342 | 0.84 | OPRK1 (0.38) | KCNN3PIK3CDPIK3R1CCNT1CDK9 | |
| SCHEMBL863800 | 0.82 | KCNN3 (0.39) | KCNN3PIK3CDPIK3R1MAPKAPK2 | |
| SCHEMBL865639 | 0.81 | KDM4E (0.37) | KCNN3PIK3CDPIK3R1MAPKAPK2 | |
| SCHEMBL865638 | 0.81 | KDM4E (0.37) | KCNN3PIK3CDPIK3R1MAPKAPK2 | |
| SCHEMBL863559 | 0.80 | MAPKAPK2 (0.35) | KCNN3PIK3CDPIK3R1PDE2AMAPKAPK2 | |
| SCHEMBL2116488 | 0.80 | IDH1 (0.43) | PIK3CDPIK3R1IDH1 | |
| SCHEMBL863558 | 0.80 | MAPKAPK2 (0.35) | KCNN3PIK3CDPIK3R1PDE2AMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | KCNN3 1471/4885PIK3CD 6/4885PIK3R1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.